[go: up one dir, main page]

DK0944617T3 - Krystaller af benzimidazolderivater og deres fremstilling - Google Patents

Krystaller af benzimidazolderivater og deres fremstilling

Info

Publication number
DK0944617T3
DK0944617T3 DK97912445T DK97912445T DK0944617T3 DK 0944617 T3 DK0944617 T3 DK 0944617T3 DK 97912445 T DK97912445 T DK 97912445T DK 97912445 T DK97912445 T DK 97912445T DK 0944617 T3 DK0944617 T3 DK 0944617T3
Authority
DK
Denmark
Prior art keywords
substituted
optionally
crystals
preparation
benzimidazole derivatives
Prior art date
Application number
DK97912445T
Other languages
English (en)
Inventor
Masayasu Kato
Toru Ishida
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17920069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0944617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DK0944617T3 publication Critical patent/DK0944617T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97912445T 1996-11-14 1997-11-13 Krystaller af benzimidazolderivater og deres fremstilling DK0944617T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30336196 1996-11-14
PCT/JP1997/004136 WO1998021201A1 (en) 1996-11-14 1997-11-13 Crystals of benzimidazole derivatives and their production

Publications (1)

Publication Number Publication Date
DK0944617T3 true DK0944617T3 (da) 2003-09-01

Family

ID=17920069

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97912445T DK0944617T3 (da) 1996-11-14 1997-11-13 Krystaller af benzimidazolderivater og deres fremstilling

Country Status (18)

Country Link
US (1) US6002011A (da)
EP (1) EP0944617B1 (da)
KR (1) KR100519576B1 (da)
CN (2) CN1171885C (da)
AT (1) ATE240314T1 (da)
AU (1) AU731776B2 (da)
CA (1) CA2269053C (da)
DE (1) DE69722027T2 (da)
DK (1) DK0944617T3 (da)
ES (1) ES2199356T3 (da)
ID (1) ID21547A (da)
IL (1) IL129724A (da)
NZ (1) NZ335145A (da)
PT (1) PT944617E (da)
TR (1) TR199901055T2 (da)
TW (1) TW385306B (da)
WO (1) WO1998021201A1 (da)
ZA (1) ZA9710255B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
WO2000045851A2 (de) * 1999-02-04 2000-08-10 Bullerdiek Joern Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
US7110444B1 (en) 1999-08-04 2006-09-19 Parkervision, Inc. Wireless local area network (WLAN) using universal frequency translation technology including multi-phase embodiments and circuit implementations
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PL333847A1 (en) * 1999-06-18 2001-01-02 Inst Farmaceutyczny Crystalline forms of lansoprozole and method of obtaining lansoprazole in pharmacologically advanthageous crystalline form
CA2375091A1 (en) 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
EP1293507B1 (en) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
ATE342263T1 (de) * 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
AU2001278755A1 (en) 2000-08-18 2002-03-04 Takeda Chemical Industries Ltd. Injections
AU2002218506A1 (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
WO2003032953A1 (en) 2001-10-17 2003-04-24 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
CA2475123A1 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
IL164153A0 (en) * 2002-03-27 2005-12-18 Teval Pharmaceutical Ind Ltd Lansoprazole polymorphs and processes for preparation thereof
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
DE60316791T2 (de) 2002-08-21 2008-07-24 Teva Pharmaceutical Industries Ltd. Verfahren zur aufreinigung von lanzoprazol
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
ATE358675T1 (de) * 2002-11-18 2007-04-15 Teva Pharma Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
EP1743893A1 (en) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US7005732B2 (en) * 2003-10-21 2006-02-28 Honeywell International Inc. Methods and systems for providing MEMS devices with a top cap and upper sense plate
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP2264025B1 (en) 2004-09-13 2013-11-06 Takeda Pharmaceutical Company Limited Method for producing lansoprazole
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
US8871273B2 (en) 2005-02-25 2014-10-28 Takeda Pharmaceutical Company Limited Method for producing granules
JPWO2006132217A1 (ja) * 2005-06-07 2009-01-08 武田薬品工業株式会社 ベンズイミダゾール化合物の塩の結晶
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
US20090175959A1 (en) 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
WO2008035189A1 (en) * 2006-09-22 2008-03-27 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of lansoprazole
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
ITMI20062481A1 (it) * 2006-12-22 2008-06-23 Recordati Chem Pharm Processo per la preparazione di lansoprazolo forma i microcristallino
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
EP2227462A1 (en) * 2007-12-31 2010-09-15 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [[[3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl]methyl]sulfinyl]-1h-benz imidazole
ES2638463T3 (es) * 2008-03-10 2017-10-20 Takeda Pharmaceutical Company Limited Cristal de compuesto de bencimidazol
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
WO2011098938A1 (en) * 2010-02-11 2011-08-18 Orchid Chemicals And Pharmaceuticals Limited Novel solvate of dexlansoprazole
US20130243859A1 (en) 2010-12-03 2013-09-19 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
SG190905A1 (en) 2010-12-27 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
CN102180866B (zh) * 2011-05-23 2013-03-13 中山大学 兰索拉唑晶型及其制备方法和应用
CN103012369B (zh) * 2011-05-23 2014-04-23 中山大学 兰索拉唑n晶型及其制备方法和应用
ES2561098T3 (es) 2011-11-30 2016-02-24 Takeda Pharmaceutical Company Limited Comprimido recubierto en seco
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CA2913106A1 (en) 2013-05-21 2014-11-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablet
CN103539729A (zh) * 2013-10-14 2014-01-29 安徽国星生物化学有限公司 一种氯甲基吡啶衍生物的工业化生产方法
CN103539728A (zh) * 2013-10-14 2014-01-29 安徽国星生物化学有限公司 一种拉唑类药物中间体氯甲基吡啶衍生物的合成方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN104817492B (zh) * 2015-05-22 2018-05-18 抚州三和医药化工有限公司 兰索拉唑中间体2-羟甲基-3-甲基-4-(2,2,2-三氟乙氧基）吡啶的分离纯化方法
KR102649498B1 (ko) 2023-12-06 2024-03-20 거산해운(주) 선사별 실시간 통합 예약 정보를 기반으로 한 화주의 해상 운송 예약 자동화 플랫폼 서비스 제공 방법, 장치 및 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives

Also Published As

Publication number Publication date
ATE240314T1 (de) 2003-05-15
CN1171885C (zh) 2004-10-20
ES2199356T3 (es) 2004-02-16
CN100355749C (zh) 2007-12-19
CN1616457A (zh) 2005-05-18
PT944617E (pt) 2003-08-29
AU731776B2 (en) 2001-04-05
CN1237167A (zh) 1999-12-01
KR20000053158A (ko) 2000-08-25
IL129724A0 (en) 2000-02-29
ZA9710255B (en) 1999-05-13
CA2269053C (en) 2006-07-18
NZ335145A (en) 2000-12-22
HK1020194A1 (en) 2000-03-31
US6002011A (en) 1999-12-14
IL129724A (en) 2004-02-19
CA2269053A1 (en) 1998-05-22
DE69722027T2 (de) 2004-03-25
AU4965297A (en) 1998-06-03
DE69722027D1 (de) 2003-06-18
ID21547A (id) 1999-06-24
EP0944617B1 (en) 2003-05-14
TW385306B (en) 2000-03-21
TR199901055T2 (xx) 1999-07-21
EP0944617A1 (en) 1999-09-29
WO1998021201A1 (en) 1998-05-22
KR100519576B1 (ko) 2005-10-07

Similar Documents

Publication Publication Date Title
DK0944617T3 (da) Krystaller af benzimidazolderivater og deres fremstilling
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
YU46916B (sh) Postupak za dobijanje kalcijum nezavisnih camp inhibitora fosfodiesteraze
CA1272482C (en) QUINOLINECARBOXYLIC ACID DERIVATIVES
RO81943B (ro) Procedeu de preparare a unor derivati de piridoxina
EA199800759A1 (ru) 2-гетароилциклогексан-1,3-дионы
UA66756C2 (uk) Сполуки піперазину та піперидину, спосіб одержання сполук та спосіб лікування розладів центральної нервової системи
ES8704445A1 (es) Procedimiento de preparar derivados aminicos
NO964698L (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
NO814113L (no) 2-oksoazetidinderivater og fremgangsmaate for deres fremstilling
DE3776044D1 (de) Pyridazinon-derivate.
NO892170D0 (no) Buten- eller propensyrederivater og fremgangsmaate for deres fremstilling.
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
DK0819108T3 (da) Fremgangsmåde til fremstilling af galanthaminderivater ved asymmetrisk reduktion
NO20073213L (no) Fremgangsmate for fremstilling av tiofenglykosidderivater
NO961537L (no) Salpetersyreestere fra derivater av 2-(2,6-dihalofenylamino)-fenylacetoksyeddiksyre, og deres fremstillingsprosedyrer
NO890158D0 (no) Fremgangsmaate for fremstilling av hydroksialkyleringsmiddel, de oppnaadde midler og deres anvendelse.
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas
DK369289A (da) Anvendelse af imidazopyrazolderivater som analgetica og antiinflammatoriske midler
DK0413278T3 (da) Anvendelse af xanthinderivater mod mavesår
DE3772852D1 (de) Thiadiazolylacetamid-derivate, verfahren zu ihrer herstellung und ihre verwendung.
NO954764L (no) Psoralen-derivater, deres fremstilling og anvendelse
ATE19629T1 (de) N-substituierte derivate des tetrahydroisophthalimids.
NO934881L (no) Benzotiazolderivater, fremgangsmåte for deres fremstilling og farmasöytisk preparat derav
DK231787D0 (da) 3-amino-dihydropyridiner, fremgangsmaade til deres fremstilling og deres anvendelse i laegemidler